Get the Stockscreener App
1.28
0.00%
0.00
Pre-market:
1.28
Igm Biosciences Inc stock is traded at $1.28, with a volume of 226.32K.
It is up +0.00% in the last 24 hours and up +8.47% over the past month.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
See More
Previous Close:
$1.28
Open:
$1.27
24h Volume:
226.32K
Relative Volume:
0.44
Market Cap:
$44.55M
Revenue:
$2.91M
Net Income/Loss:
$-220.40M
P/E Ratio:
-0.3516
EPS:
-3.64
Net Cash Flow:
$-176.15M
1W Performance:
+0.79%
1M Performance:
+8.47%
6M Performance:
-24.26%
1Y Performance:
-89.62%
1-Day Range:
$1.26
$1.28
1-Week Range:
$1.26
$1.29
52-Week Range:
$0.92
$22.50
Igm Biosciences Inc Stock (IGMS) Company Profile
Name
Igm Biosciences Inc
Sector
Industry
Phone
650-965-7873
Address
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW
Compare IGMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IGMS
Igm Biosciences Inc
|
1.28 | 77.04M | 2.91M | -220.40M | -176.15M | -3.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Igm Biosciences Inc Stock (IGMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-10-25 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-10-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-10-25 | Downgrade | Stifel | Buy → Hold |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-01-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-24 | Downgrade | Truist | Buy → Hold |
| Feb-09-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-22 | Resumed | Jefferies | Buy |
| Oct-17-22 | Initiated | JP Morgan | Neutral |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Dec-13-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-21 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-26-21 | Initiated | Morgan Stanley | Overweight |
| Jan-29-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-22-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-17-20 | Initiated | Robert W. Baird | Outperform |
| Jul-01-20 | Initiated | H.C. Wainwright | Buy |
| May-28-20 | Initiated | SunTrust | Buy |
| Apr-22-20 | Initiated | Wedbush | Outperform |
| Oct-14-19 | Initiated | Guggenheim | Buy |
| Oct-14-19 | Initiated | Jefferies | Buy |
| Oct-14-19 | Initiated | Piper Jaffray | Overweight |
| Oct-14-19 | Initiated | Stifel | Buy |
View All
Igm Biosciences Inc Stock (IGMS) Latest News
Will IGM Biosciences Inc. stock benefit from interest rate changesHigh-profit stock alerts - jammulinksnews.com
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives $5.50 Consensus Price Target from Brokerages - MarketBeat
What analysts say about IGM Biosciences Inc. stockStrong return on investment - Autocar Professional
IGM Biosciences Inc. Stock Analysis and ForecastHigh-performance investment picks - Autocar Professional
What drives IGM Biosciences Inc. stock priceExtraordinary profit generation - Autocar Professional
Is IGM Biosciences Inc. a good long term investmentRapidly growing investment returns - jammulinksnews.com
Stockholder Sues IGM Biosciences for Alleged SEC Violations - Bloomberg Law News
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 5.9%Here's What Happened - MarketBeat
IGM Biosciences, Inc. (NASDAQ:IGMS) Receives Consensus Recommendation of “Reduce” from Brokerages - Defense World
Fierce Biotech Layoff Tracker 2025: Sail shrinks crew again; Sarepta lays off 500 staffers - Fierce Biotech
IGM Biosciences (NASDAQ:IGMS) Trading Down 5.9% – Here’s Why - Defense World
Why IGM Biosciences Inc. stock attracts strong analyst attentionConsistent High Return Strategy - beatles.ru
Concentra Group (CON) to Acquire IGM Biosciences - MSN
What makes IGM Biosciences Inc. stock price move sharplyFree Stock Market Real-Time Monitoring - Newser
How IGM Biosciences Inc. stock performs during market volatilityFree Access to Group - Newser
In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal - insights.citeline.com
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: GMS, IGMS, MRC, and GRYP - The Malaysian Reserve
IGM Biosciences to be acquired by Concentra - The Pharma Letter
Regeneron bispecific approved for myeloma; Concentra to buy IGM - BioPharma Dive
Concentra to acquire IGM Biosciences for $1.247 per share plus CVR - Investing.com Nigeria
Concentra Biosciences, LLC agreed to acquire IGM Biosciences, Inc. for $76.3 million. - MarketScreener
IGM Biosciences Shares Surge on Takeover Agreement with Concentra - MSN
IGM Biosciences Gets Snapped Up In Concentra Deal - Finimize
IGM Biosciences stock soars after Concentra acquisition deal - Investing.com
IGM Biosciences Enters Definitive Merger Agreement with Concentra Biosciences for Acquisition - Nasdaq
IGM Biosciences stock soars after Concentra acquisition deal By Investing.com - Investing.com UK
IGM Biosciences, Inc.(NasdaqGS: IGMS) dropped from Russell 3000 Index - MarketScreener
IGM Biosciences, Inc. (NASDAQ:IGMS) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Igm biosciences CFO Tahir Misbah sells $1,825 in stock - Investing.com
Igm Biosciences Inc Stock (IGMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):